TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6151503
Drug: Antihypertensive regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive regimens containing a beta-blocker (oxprenolol)
Study: 6151503
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy not containing a beta-blocker
Study: 29061540
Drug: Suspicious digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspicious digital rectal examination
Study: 27569432
Drug: Abnormal prostate
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal prostate specific antigen (4 ng/ml or greater)
Study: 27569432
Drug: Suspicious digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspicious digital rectal examination and abnormal prostate specific antigen (combined)
Study: 10732848
Drug: HMG-CoA reductase
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitor (simvastatin)
Study: 26749408
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg orally
Study: 26749408
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once daily
Study: 22201295
Drug: Flucloxacillin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin 2 g (5-minute infusion)
Study: 20063994
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg misoprostol 3‐hourly (group A)
Study: 20063994
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg misoprostol 6‐hourly (group B)
Study: 20063994
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg misoprostol 12‐hourly (group C)
Study: 17727927
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by radical surgery
Study: 17727927
Drug: Various drug
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drug regimens for neoadjuvant chemotherapy
Study: 12693427
Drug: Amisulpride (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50-300 mg daily)
Study: 7591492
Drug: Standard weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weekly intervention (6 weekly sessions)
Study: 6754634
Drug: Non-treatment (control)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment (control)
Study: 28345400
Drug: A‐mix (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐mix (3 g/dose)
Study: 25496283
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care family therapy (UC-FT)
Study: 8425702
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg captopril
Study: 3118827
Drug: TPN supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN supplemented with ornithine‐alpha‐ketoglutarate (0.35 g/kg bw/day)
Study: 31747326
Drug: EGCG (440
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (440 μM) administered at first onset of ARIE and then weekly after final radiotherapy
Study: 31747326
Drug: EGCG (440
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (440 μM) administered for ARIE
Study: 30112772
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg as first-line treatment
Study: 30112772
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg as first-line treatment
Study: 18394501
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group TRP(8)
Study: 18394501
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group TRP(30)
Study: 17109664
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS) 0.25-1 mg daily
Study: 12891539
Drug: Oral tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tacrolimus 0.2 mg. kg(‐1). day(‐1)
Study: 10492065
Drug: Vincristine, Prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine, Prednisone, and L-asparaginase (VPL)
Study: 8731073
Drug: Low‐dose artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐dose artificial light (0.5 h@2800 lux)
Study: 8731073
Drug: Natural light
Normalized name: OCTINOXATE 138 mg in 4 mL / TITANIUM DIOXIDE 123 mg in 4 mL TOPICAL CREAM [SHISEIDO WHITE LUCENT ONMAKEUP SPOT CORRECTING SERUM NATURAL LIGHT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural light treatment (1‐h morning walk outdoors)
Study: 1836687
Drug: 3 chemotherapeutic
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 chemotherapeutic regimens at 3-monthly intervals
Study: 22316141
Drug: 6-weekly group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-weekly group-based skills training for adolescents followed by 6-weekly targeted newsletters for caregivers (Group 1)
Study: 12716275
Drug: Selective Serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Serotonin Reuptake Inhibitors (SSRIs) (N = 749)
Study: 23021480
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (P-ESDM and community treatment)
Study: 3139279
Drug: leutinizing hormone‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: leutinizing hormone‐releasing hormone (LHRH) analog buserelin
Study: 21098692
Drug: Extended-release hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release hydromorphone 16 mg after a high-fat breakfast
Study: 21098692
Drug: Immediate-release hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release hydromorphone 16 mg daily dose (4 mg qid) in the fasted state
Study: 19408811
Drug: Calcium pre-rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium pre-rinse (150 mmol/L)
Study: 3513009
Drug: Unchanged conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged conventional treatment
Study: 23390778
Drug: Original clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original clopidogrel 600 mg
Study: 23390778
Drug: Generic clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic clopidogrel 600 mg
Study: 18284648
Drug: Renzapride 1
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 1 mg/day
Study: 18284648
Drug: Renzapride 2
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 2 mg/day
Study: 18284648
Drug: Renzapride 4
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renzapride 4 mg/day (women)
Study: 15625258
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia alone or in combination with placebo blocks
Study: 12895220
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy with tetracycline
Study: 12895220
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy with metronidazole
Study: 12895220
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy with metronidazole (with metronidazole resistance)
Study: 8351363
Drug: Lytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lytic therapy (both FI and CI)
Study: 19266381
Drug: Viagra plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viagra plus sex therapy (VST)
Study: 15454133
Drug: Robotic telerounding
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic telerounding (substitution of one daily bedside round with a robotic telerounding visit)
Study: 15454133
Drug: Standard once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard once-daily attending bedside rounds
Study: 8391282
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg
Study: 7599015
Drug: Clindamycin 600
Normalized name: clindamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 600 mg
Study: 12679215
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg (Black patients)
Study: 12679215
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg (Black patients)
Study: 12679215
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg (White patients)
Study: 12679215
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg (White patients)
Study: 30787343
Drug: d[Ca] 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: d[Ca] 1.75 mmol/L
Study: 30787343
Drug: d[Ca] 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: d[Ca] 1.25 mmol/L
Study: 28893387
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care + Pulsed Electromagnetic Frequency (PEMF) therapy
Study: 25425475
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously every 4 weeks (Q4W)
Study: 19176543
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg asoprisnil daily for 12 weeks
Study: 19176543
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg asoprisnil daily for 12 weeks
Study: 17534812
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation
Study: 9674466
Drug: Flutter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutter treatment
Study: 8592286
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and continuous passive motion (n = 21)
Study: 8592286
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy only (n = 18)
Study: 2228322
Drug: sulglycotide (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulglycotide (oral, 200 mg t.i.d. for 6 weeks, n = 93)
Study: 346631
Drug: 50% lactulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% lactulose syrup
Study: 27899298
Drug: 4% menthol
Normalized name: LEVOMENTHOL 0.04 mg in 1 mL TOPICAL GEL [Auvon 4% Menthol Pain Relief Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% menthol gel (0.017mL·cm‐2)
Study: 26497109
Drug: Fluticasone furoate/vilanterole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterole (FF/VI) 200/25 μg
Study: 9041463
Drug: High-dose IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN
Study: 17614242
Drug: Brief family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief family treatment (BFT)
Study: 17614242
Drug: Continuing care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing care (regardless of treatment condition)
Study: 12616666
Drug: Dispersible tablets
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablets of everolimus (0.8 mg/m2, maximum 1.5 mg, bid)
Study: 12616666
Drug: Dispersible tablets
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablets of everolimus (1.5 mg) after a high-fat meal
Study: 12616666
Drug: Conventional tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablets of everolimus (1.5 mg)
Study: 9026479
Drug: Loxiglumide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loxiglumide infusion
Study: 6370811
Drug: Flunarizine 10
Normalized name: flunarizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10 mg daily
Study: 3903501
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy combined with chemotherapy
Study: 30376687
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy alone
Study: 17519730
Drug: Midazolam bolus
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam bolus of 0.05 mg/kg plus continuous infusion 0.08 mg/kg per hour (both groups)
Study: 9739441
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (CMF)
Study: 9739441
Drug: Temporary ovarian
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary ovarian ablation by treatment with a LHRH analogue (Zoladex, Goserlin)
Study: 21822145
Drug: SL65.0472‐00 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SL65.0472‐00 (20 mg)
Study: 21822145
Drug: Sumatriptan (agonist)
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan (agonist)
Study: 17717114
Drug: Quercetin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1,000 mg/day)
Study: 8633188
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lithium carbonate
Study: 8633188
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lithium carbonate
Study: 22681960
Drug: Oral lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lansoprazole
Study: 15545311
Drug: MP (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP (100 mg)
Study: 11684534
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (105 mg/d)
Study: 11684534
Drug: High-iron diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-iron diet (2.25 mg/d)
Study: 2509120
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment for the first six postoperative weeks
Study: 2509120
Drug: No anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-inflammatory treatment (Control)
Study: 775991
Drug: Contraceptive medication
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive medication
Study: 2444309
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma (FFP) - 2 units daily for 3 days
Study: 26907840
Drug: Concurrent Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Strength and Endurance Training 3:1 (CT3)
Study: 26907840
Drug: Concurrent Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Strength and Endurance Training 1:1 (CT1)
Study: 22147112
Drug: BAY41-6551 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY41-6551 400 mg every 24 hours (q24h) with aerosol placebo
Study: 17845589
Drug: Beclomethasone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone plus formoterol combination
Study: 772759
Drug: Indomethacin (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (therapeutic doses)
Study: 772759
Drug: Acetyl salicylic
Normalized name: Acetyl salicylic acid specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl salicylic acid (therapeutic doses)
Study: 17720659
Drug: LPV/r 400/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 400/300 mg bid
Study: 17720659
Drug: LPV/r 667/167
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 667/167 mg bid
Study: 10575912
Drug: Omeprazole with
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole with amoxicillin and clarithromycin
Study: 10575912
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth with amoxicillin and metronidazole
Study: 6614325
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg intravenously before operation)
Study: 6614325
Drug: Ticarcillin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin (5 g intravenously before operation)
Study: 17165349
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 1.5 mg/kg
Study: 30741832
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol 0.5 mg/kg and lidocaine 1.5 mg/kg
Study: 16456408
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor
Study: 23028897
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg selenium/d
Study: 23028897
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg selenium/d
Study: 23028897
Drug: 300 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 µg selenium/d
Study: 20137761
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg b.i.d for 7 days along with standard doses of aspirin and clopidogrel
Study: 18608093
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg) - Creatine (10 g) twice daily for six months
Study: 16102404
Drug: 2-phase treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-phase treatment (full orthodontic treatment with fixed appliances after 1 year)
Study: 10872368
Drug: Radical anterior
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical anterior resection with bone grafting plus six months of daily isoniazid plus rifampicin (Rad6)
Study: 23474245
Drug: Intensified antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified antihypertensive therapy
Study: 1759583
Drug: Topical glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticoids
Study: 21724155
Drug: Medicine for
Normalized name: IBUPROFEN 200 mg ORAL TABLET [Ibuprofen Fast relief medicine for pain]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine for the Earth (MFTE)
Study: 22964475
Drug: Calcium (2
Normalized name: calcium (2ξ)-D-gluco-heptonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (2 g/day)
Study: 11722712
Drug: Immune milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune milk treatment (45 g of immune milk powder twice a day for 3 months)
Study: 11722712
Drug: Immune milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune milk treatment
Study: 11722712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral habit intervention only)
Study: 9220212
Drug: cilazapril plus
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril plus conventional therapy (diuretics and digitalis)
Study: 9220212
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional therapy (diuretics and digitalis)
Study: 31230020
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg melatonin per day
Study: 25929739
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg b.i.d.
Study: 23782529
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg q.d.
Study: 16967045
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal 50 microg/spray b.i.d. and Fenoxifenadine 180 mg tablets q.d.
Study: 12775344
Drug: Altered synaptic
Normalized name: Synanthic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altered synaptic inactivity due to changes in glycoconjugate metabolism and membrane composition.
Study: 22091738
Drug: CAPABLE intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAPABLE intervention (occupational therapy, nursing, handyman visits)
Study: 19631127
Drug: Adrenaline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline group (0.5 mL of 1:1000 adrenaline in 500.0 mL of fortified balanced salt solution)
Study: 29273872
Drug: Lansoprazole orally
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole orally disintegrating (OD) tablets (30 mg) given orally once daily for 8 weeks (56 days) starting the day before ESD
Study: 20693267
Drug: Nutrient and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient and supplement intakes (lycopene, long-chain n-3 fatty acids, vitamin D, vitamin E, selenium)
Study: 9374251
Drug: Latanoprost 50
Normalized name: Latanoprost 50 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 50 microg/ml, one drop twice daily
Study: 3893619
Drug: Phenol Injection
Normalized name: Phenol Injection
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenol Injection
Study: 20530437
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone at 400 mg daily for 10 days/month for 6 months
Study: 10595786
Drug: Beta-carotene (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (15 mg/day)
Study: 10595786
Drug: Lycopene (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (15 mg/day)
Study: 27736846
Drug: Paclitaxel treatment
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel treatment
Study: 27566263
Drug: Alectinib 150
Normalized name: alectinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib 150 mg capsule
Study: 27566263
Drug: Alectinib 20/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib 20/40 mg capsules
Study: 2907315
Drug: Nitrazepam 10
Normalized name: nitrazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 10 mg